Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours | terminated | Phase 1 | 20 | Almac DiscoveryINDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)(AL3818) | terminated | Phase 1 / Phase 2 | 12 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jun 19, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | terminated | Phase 1 / Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 98 | Verastem, Inc.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
| NCT00996502 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01741753 | BKM120+Abiraterone Acetate for Metastatic CRPC | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02478125 | Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01262664 | A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02539719 | Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer | terminated | Phase 1 | 74 | StemcentrxINDUSTRY | 1 | Jan 4, 2019 | clinicaltrials |
| NCT00924807 | Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Medical CenterOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00102622 | Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT02589366 | Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium | terminated | Phase 1 | 2 | University of California, San DiegoOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer(KHLAD) | terminated | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT00084890 | Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix | terminated | Phase 1 | 15 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT01983709 | Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer(MSC) | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT01335204 | Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Medical University of South CarolinaOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01197664 | Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery | terminated | Phase 1 | 2 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02284971 | Pilot Study of SBRT and CDX-1127 in Prostate Cancer(Prostate-04) | terminated | Phase 1 | 2 | James Larner, MDOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT00096304 | Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 36 | Medical University of South CarolinaOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT02708511 | Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer | terminated | Phase 1 | 2 | Sanjiv Sam GambhirOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT02349139 | Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 1 | 27 | Asana BioSciencesINDUSTRY | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02110953 | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver | terminated | Phase 1 | 2 | Fox Chase Cancer CenterOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT00004261 | EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | terminated | Phase 1 | — | University Health Network, TorontoOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT00303888 | Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | terminated | Phase 1 | 31 | Yale UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00287859 | Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 1 | 5 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00278434 | Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 | terminated | Phase 1 | 12 | University of California, San FranciscoOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT01677845 | Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer | terminated | Phase 1 | 9 | NYU Langone HealthOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01642732 | Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer | terminated | Phase 1 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02429804 | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 4 | Stanford UniversityOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01494012 | Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02483884 | PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Lantheus Biosciences Ltd.INDUSTRY | 2 | Mar 22, 2017 | clinicaltrials |
| NCT01155791 | Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer | terminated | Phase 1 | 2 | Sandy SrinivasOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT00629577 | Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples(SAGE) | terminated | Phase 1 | 50 | British Columbia Cancer AgencyOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT01913197 | Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy | terminated | Phase 1 / Phase 2 | 2 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | terminated | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 11, 2019source: clinicaltrials